Publications: Bordetella pertussis

2014 to present:

  • McNamara, L, Skoff, T, Faulkner A, et al. Reduced severity of pertussis in persons with age-appropriate pertussis vaccination — United States, 2010–2012. Clin Infect Dis. 2017;65(5):811–18
  • Weigand M, Peng Y, Loparev V, et al. The history of Bordetella pertussis genome plasticity and conserved rearrangement. J Bacteriol. 2017;199(8): e00806–16.
  • Blain AE, Lewis M, Banerjee E, et al. An assessment of the cocooning strategy for preventing infant pertussis: United States, 2011. Clin Infect Dis. 2016;63(Suppl 4):S221–6.
  • Cassiday PK, Skoff TH, Jawahir S, Tondella ML. Changes in the predominance of pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates, United States, 2000-2012. Emerg Infect Dis. 2016;22(3):442-8.
  • Williams MM, Sen K, Weigand MR, et al. Bordetella pertussis strain lacking pertactin and pertussis toxin. Emerg Infect Dis. 2016;22(2):319-22.
  • Martin SW, Pawloski L, Williams M, et al. Pertactin-negative Bordetella pertussis strains: Evidence for a possible selective advantage. Clin Infect Dis. 2015;60(20):223-7.
  • Skoff TH, Baumbach J, Cieslak PR. Tracking pertussis and evaluating U.S. control measures through the Emerging Infections Program Network’s Enhanced Pertussis Surveillance System. Emerg Infect Dis. 2015;21(9):1568-73.
  • Skoff TH, Kenyon C, Cocoros N, et al. Sources of infant pertussis infection in the United Statesexternal icon. Pediatrics. 2015;136(4):635-41. doi: 10.1542/peds.2015-1120. Epub 2015 Sep 7.
  • Pawloski LC, Queenan AM, Cassiday PK, et al. Prevalence and molecular characterization of pertactin-decficient Bordetella pertussis in the US. Clin Vaccine Immunol. 2014;21(2):119-25.